Vismodegib

Vismodegib

• Samples availability: Q4 2024
• Production facility suitable for ANVISA, FDA and European requirements
• Straightforward and cost effective process
• Bask integration with 4 in-house steps
• High quality of the key intermediate sources
• Production in brand new facility with state-of-the-art equipment

Drug description

Vismodegib is used in adults to treat basal cell carcinoma that has spread to other parts of the body (metastatic), or that has come back after surgery, or cannot be treated with surgery or radiation.

Disclaimer:Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subject to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer’s responsibility and liability to check the patent situation of the product in the import market(s).

‍